Skip to main content
Equibles

CRDL · Cardiol Therapeutics Inc. · Metrics

Track CRDL — free

Use CRDL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRDL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.16 +0.06 (+5.09%)
Rebalance outlook locked
Market Cap
$139.74M
Shares
121.51M
Volume · Oct 20 652.09K Avg daily vol (3M) 1.4M

CRDL metrics

46 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.15
Market cap
$139.74M

Price action

20 metrics
Price change (1W)
-6.8%
Price change (30D)
-40.9%
Price change (3M)
-10.9%
Price change (6M)
-27.2%
Price change (YTD)
+15.3%
Price change (1Y)
+6.8%
Trailing year
Price change (5Y)
-75.8%
52-week high
$2.29
52-week low
$0.93
Change from 52-week high
-51.9%
Change from 52-week low
+18.8%
Annualized volatility
63.2%
Annualized volatility (3M)
70.7%
Beta
1.3
RSI (14D)
20.5
Price vs SMA 50
-36.3%
Price vs SMA 200
-15.1%
Avg volume (3M)
1.41M
Relative volume
0.5
Average dollar volume
$2.34M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
121.51M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
10.3
reciprocal yield 9.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-49,091.9%
Trailing 12 months
Net margin
-40,170.4%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.18

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-189.2%
Return on assets
-143.2%
Debt / equity
—
Current ratio
4.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$15.62M
Total assets
$17.23M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
53
13F filer change QoQ
+6
Institutional ownership
24.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.7%
Holder tenure
13.7
Price vs estimated holder cost
-1.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1702123 CUSIP 14161Y200 13F (30d) 3 filings 3 filers Visit website Investor relations